

Position Statement: To be adhered to in line with the CCG Prescribing Policy

Treatment	THC:CBD oromucosal spray (Sativex®) to treat moderate to severe spasticity in adults with multiple sclerosis
Commissioning position	<p>THC:CBD oromucosal spray for multiple sclerosis (MS) is not supported for people registered with a Herefordshire or Worcestershire GP or resident within Herefordshire and Worcestershire and not currently registered with any GP:</p> <p>The Prescribing Committee did not consider THC:CBD oromucosal spray suitable for use within Herefordshire and Worcestershire due to limitations in existing clinical trial data and cost-effectiveness evidence.</p> <p>The funding of THC:CBD oromucosal spray will only be considered by Herefordshire & Worcestershire Clinical Commissioning Group (CCG) in exceptional clinical circumstances through the individual funding request (IFR) process.</p>
Summary of Evidence	<p>In consideration of this position statement the committee considered:</p> <ul style="list-style-type: none"> ➤ New and existing trial data for clinical effectiveness, reviewed by the National Institute for Health and Care Excellence (NICE) NG 144¹; studies found an improvement in spasticity. However, not all studies were in relation to THC:CBD oromucosal spray and several used unlicensed doses, i.e. above the recommended maximum of 12 sprays daily. The remaining studies were of poor quality and limitations. ➤ No head to head studies with other treatments for spasticity were identified and so there is a lack of evidence suggesting THC:CBD oromucosal spray could be used in place of currently recommended treatments. ➤ No new cost-effective evidence was reviewed by NICE; only two relevant studies were identified and cited again from previous NICE reviews. The two cost-utility analyses were described as containing 'very serious limitations and 'potentially serious limitations'¹
Cost	The annual cost of THC:CBD oromucosal spray (Sativex®) is £5,100 per patient, assuming a maximum of 12 sprays are administered per day (Drug Tariff January 2020) ²
Approved Date for Review	<p>March 2020</p> <p>March 2023 <i>or sooner if additional national guidance and/or published evidence is made available</i></p>
References	<ol style="list-style-type: none"> 1. NICE (2019). Cannabis-based medicinal products: Evidence review for spasticity; NICE guideline NG144. Available at: https://www.nice.org.uk/guidance/ng144/evidence/c-spasticity-pdf-6963831760 Accessed: 28/11/2019. 2. NHSBSA (2020) Drug Tariff January 2020. Available at: http://www.drugtariff.nhsbsa.nhs.uk/#/00770298-DC/DC00770293/Home Accessed: 08/01/2020.